PCNA 抑制作为宫颈癌治疗策略的潜力。
The potential of PCNA inhibition as a therapeutic strategy in cervical cancer.
机构信息
Division of Biology, Kansas State University, Manhattan, Kansas, USA.
Beckman Research Institute of City of Hope, Duarte, California, USA.
出版信息
J Med Virol. 2023 Nov;95(11):e29244. doi: 10.1002/jmv.29244.
Abstract
Cervical cancers are the fourth most common and most deadly cancer in women worldwide. Despite being a tremendous public health burden, few novel approaches to improve care for these malignancies have been introduced. We discuss the potential for proliferating cell nuclear antigen (PCNA) inhibition to address this need as well as the advantages and disadvantages for compounds that can therapeutically inhibit PCNA with a specific focus on cervical cancer.
摘要
宫颈癌是全球女性中第四常见和最致命的癌症。尽管它给公共卫生带来了巨大负担，但很少有新的方法来改善这些恶性肿瘤的治疗。我们讨论了增殖细胞核抗原 (PCNA) 抑制的潜力，以满足这一需求，以及具有特定治疗抑制 PCNA 作用的化合物的优缺点，重点是宫颈癌。
相似文献
1
The potential of PCNA inhibition as a therapeutic strategy in cervical cancer.PCNA 抑制作为宫颈癌治疗策略的潜力。
J Med Virol. 2023 Nov;95(11):e29244. doi: 10.1002/jmv.29244.
2
Up-regulation of proliferating cell nuclear antigen (PCNA) is closely associated with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer.增殖细胞核抗原（PCNA）的上调与高危型人乳头瘤病毒（HPV）及宫颈上皮内瘤变（CIN）的进展密切相关，但不能预测宫颈癌的疾病转归。
Eur J Obstet Gynecol Reprod Biol. 2007 Feb;130(2):223-31. doi: 10.1016/j.ejogrb.2006.10.007. Epub 2006 Nov 13.
3
[Comparative study of HPV infection and proliferating cell nuclear antigen of uterine cervix].子宫颈人乳头瘤病毒感染与增殖细胞核抗原的对比研究
Nihon Sanka Fujinka Gakkai Zasshi. 1993 Sep;45(9):967-72.
4
Expression of the proliferating cell nuclear antigen in cervical neoplasia.增殖细胞核抗原在宫颈肿瘤中的表达。
Int J Gynecol Pathol. 1994 Oct;13(4):337-41. doi: 10.1097/00004347-199410000-00007.
5
6
Decrease in tumor volume and histologic response to intraarterial neoadjuvant chemotherapy in patients with cervical and endometrial adenocarcinoma.宫颈癌和子宫内膜腺癌患者肿瘤体积的减小及对动脉内新辅助化疗的组织学反应
Gynecol Oncol. 1997 May;65(2):258-64. doi: 10.1006/gyno.1997.4638.
7
Long noncoding RNA CCHE1 promotes cervical cancer cell proliferation via upregulating PCNA.长链非编码RNA CCHE1通过上调增殖细胞核抗原促进宫颈癌细胞增殖。
Tumour Biol. 2015 Sep;36(10):7615-22. doi: 10.1007/s13277-015-3465-4. Epub 2015 Apr 29.
8
Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer.p16INK4A、p14ARF、p53及增殖细胞核抗原表达改变在宫颈癌进展中的预测意义
Clin Cancer Res. 2004 Apr 1;10(7):2407-14. doi: 10.1158/1078-0432.ccr-03-0242.
9
The correlation between HPV infection and cell proliferative activity in uterine cervical adenocarcinoma.人乳头瘤病毒感染与子宫颈腺癌中细胞增殖活性的相关性
Tohoku J Exp Med. 1993 Apr;169(4):279-88. doi: 10.1620/tjem.169.279.
10
[Expression of PCNA antigen in cellular proliferative activity of cervical carcinoma].[增殖细胞核抗原（PCNA）抗原在宫颈癌细胞增殖活性中的表达]
Ginekol Pol. 2000 Sep;71(9):1164-8.
引用本文的文献
1
Analysis of immune cell infiltration in the tumor microenvironment of cervical cancer and its impact on immunotherapy.宫颈癌肿瘤微环境中免疫细胞浸润分析及其对免疫治疗的影响。
Front Oncol. 2025 Jul 3;15:1608597. doi: 10.3389/fonc.2025.1608597. eCollection 2025.
2
Deferiprone ameliorates cisplatin induced peripheral neurotoxicity via ferritinophagy adjustment.去铁酮通过铁自噬调节减轻顺铂诱导的周围神经毒性。
Sci Rep. 2025 Feb 6;15(1):4485. doi: 10.1038/s41598-025-87628-x.
3
X-ray crystal structure of proliferating cell nuclear antigen 1 from Aeropyrum pernix.嗜热古菌 1 型增殖细胞核抗原的 X 射线晶体结构。
Acta Crystallogr F Struct Biol Commun. 2024 Nov 1;80(Pt 11):294-301. doi: 10.1107/S2053230X24009518. Epub 2024 Oct 9.
4
Anti-filarial efficacy of : unravelling the underlying mechanisms through biochemical, HRAMS proteomics and MD simulation approaches.抗丝虫病功效：通过生化、高分辨质谱蛋白质组学和分子动力学模拟方法揭示潜在机制
RSC Adv. 2024 Aug 12;14(35):25198-25220. doi: 10.1039/d4ra03461a.
5
The bacterial DNA sliding clamp, β-clamp: structure, interactions, dynamics and drug discovery.细菌 DNA 滑动夹，β-夹：结构、相互作用、动力学和药物发现。
Cell Mol Life Sci. 2024 May 30;81(1):245. doi: 10.1007/s00018-024-05252-w.
本文引用的文献
1
Small molecule targeting of transcription-replication conflict for selective chemotherapy.小分子靶向转录-复制冲突用于选择性化疗。
Cell Chem Biol. 2023 Oct 19;30(10):1235-1247.e6. doi: 10.1016/j.chembiol.2023.07.001. Epub 2023 Aug 1.
2
For Better or Worse: Modulation of the Host DNA Damage Response by Human Papillomavirus.好或坏：人乳头瘤病毒对宿主 DNA 损伤反应的调节。
Annu Rev Virol. 2023 Sep 29;10(1):325-345. doi: 10.1146/annurev-virology-111821-103452. Epub 2023 Apr 11.
3
Targeting the / deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights.用聚（ADP-核糖）聚合酶（PARP）抑制剂靶向缺陷型癌症：临床结果与机制洞察
Front Cell Dev Biol. 2023 Mar 22;11:1133472. doi: 10.3389/fcell.2023.1133472. eCollection 2023.
4
Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib.单药PARP抑制剂奥拉帕利成功治疗复发性宫颈癌
Case Rep Obstet Gynecol. 2022 Oct 25;2022:6579715. doi: 10.1155/2022/6579715. eCollection 2022.
5
Targeted degradation of PCNA outperforms stoichiometric inhibition to result in programed cell death.靶向降解增殖细胞核抗原（PCNA）比化学计量抑制更有效，从而导致程序性细胞死亡。
Cell Chem Biol. 2022 Nov 17;29(11):1601-1615.e7. doi: 10.1016/j.chembiol.2022.10.005. Epub 2022 Oct 31.
6
PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed.用于晚期或转移性宫颈癌的PD-1/PD-L1抑制剂：从实验台到病床。
Front Oncol. 2022 Oct 14;12:849352. doi: 10.3389/fonc.2022.849352. eCollection 2022.
7
HPV 16 E7 alters translesion synthesis signaling.HPV16 E7 改变了跨损伤合成信号。
Virol J. 2022 Oct 20;19(1):165. doi: 10.1186/s12985-022-01899-8.
8
Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial.在坦桑尼亚，比较 9-14 岁女孩接种一剂 HPV 疫苗（DoRIS）与历史队列中接种一剂 HPV 疫苗：一项随机对照试验的免疫桥接分析。
Lancet Glob Health. 2022 Oct;10(10):e1485-e1493. doi: 10.1016/S2214-109X(22)00306-0.
9
Comparison of global treatment guidelines for locally advanced cervical cancer to optimize best care practices: A systematic and scoping review.比较局部晚期宫颈癌的全球治疗指南以优化最佳护理实践：一项系统和范围界定综述。
Gynecol Oncol. 2022 Nov;167(2):360-372. doi: 10.1016/j.ygyno.2022.08.013. Epub 2022 Sep 10.
10
HPV vaccination and cervical cancer screening.人乳头瘤病毒疫苗接种与宫颈癌筛查
Lancet. 2022 May 21;399(10339):1939. doi: 10.1016/S0140-6736(22)00110-6.
Zotero 插件